WHO approves Coronavac emergency use, China's second Covid-19 vaccine, developed by Sinovac company.

World Health Organization (WHO) Today's approval of Emergency use of Coronavac, Vaccine Covid-19 of Sinovac Company, ensuring countries, donors, bidding agencies and communities that it responds

At the beginning of the month ago, WHO also approved the Covid-19 Vaccine of Chinese Pharmaceutical Sinopharm to use in an emergency.

A Covid-19 vaccine box produced by China's Sinovac biotechnology firm.

WHO's emergency use list helps countries around the world quickly approve and importing vaccines to inject people, especially those who do not have their own international management agencies.

Vaccines approved by WHO are also included in the Covax program, the global vaccine distribution initiative is mainly provided to poor countries, places that are facing a large issue of vaccine sources.

The Statement of the Independent Expert Committee recommends Sinovac's Vaccine Covid-19 for adults over 18 years of age, with the second dose after the first dose of 2-4 weeks.

WHO Technical Advisory Group, started meeting on May 5, making a decision after considering the latest clinical data on the effectiveness and safety of the Sinovac vaccine, as well as the production activities of the public

Chinese Covid-19 vaccine, produced by Cansino Biologics, has submitted clinical trial data, but WHO has not yet scheduled the evaluation.

Sinovac said it has provided over 600 million doses of domestic and foreign vaccines as late last month, including more than 430 million doses used.